FHI
Federated Hermes, Inc.
FHI's fundamentals are mixed: revenue grew 13%, while its operating margin held steady at 28%. At 11x earnings, it's trading right at its usual valuation. Analysts expect earnings growth.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
FHI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
FHI's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like FHI.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
FHI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.5x | $52.45 | -17% |
| Fair | 11x | $62.14 | -2.2% |
| Current | 11x | $63.52 | — |
| Forward | 11x | $63.52 | — |
| Expensive | 13x | $71.76 | +13% |
Historical ranges are pointers, not guarantees.
FHI's PE is in its fair range at 11.5x. If earnings grow as analysts expect, today's price would be 10.8x next year's earnings.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
FHI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
FHI has the edge over IREN on the outlook, with more favorable earnings expectations.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
FHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.89 | +6.6% |
| Q3 2026 | $5.53 | +14% |
| Q2 2026 | $5.37 | +18% |
| Q1 2026 | $5.15 | +43% |
| Q4 2025 | $5.13 | +59% |
| Q3 2025 | $4.83 | +56% |
| Q2 2025 | $4.55 | +57% |
| Q1 2025 | $3.59 | +2.3% |
| Q4 2024 | $3.23 | -5% |
FHI has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
FHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $507.3M | +8.1% |
| Q2 2026 | $502.8M | +18% |
| Q1 2026 | $479M | +13% |
| Q4 2025 | $482.8M | +14% |
| Q3 2025 | $469.4M | +15% |
| Q2 2025 | $424.8M | +5.5% |
| Q1 2025 | $423.5M | +6.9% |
| Q4 2024 | $424.7M | +8.5% |
FHI's revenue has grown year over year for nine quarters in a row: $507M last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +2.6 points |
| Q2 2026 | 26% | -1.1 points |
| Q1 2026 | 26% | -4.7 points |
| Q4 2025 | 28% | +2.1 points |
| Q3 2025 | 28% | +0.2 points |
| Q2 2025 | 28% | +17 points |
| Q1 2025 | 31% | +6.2 points |
| Q4 2024 | 26% | -0.2 points |
FHI has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
FHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $120.2M | +18% |
| Q2 2026 | $79.7M | +343% |
| Q1 2026 | $24M | +80% |
| Q4 2025 | $161.6M | +28% |
| Q3 2025 | $101.6M | -15% |
| Q2 2025 | $18M | -78% |
| Q1 2025 | $13.3M | -1% |
| Q4 2024 | $126.2M | -1% |
FHI has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
FHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -950K shares |
| 1 year | -4.1% | -3.1M shares |
| 3 years | -15% | -12.7M shares |
| 5 years | -24% | -22.3M shares |
| Available history | -27% | -26.3M shares |
FHI has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $57.4M |
| Q2 2026 | $64M |
| Q1 2026 | $64.7M |
| Q4 2025 | $77.1M |
| Q3 2025 | $21,000 |
| Q2 2025 | $65.5M |
| Q1 2025 | $120.1M |
| Q4 2024 | $23.4M |
FHI spent $263M buying back its own shares over the past year, up 26% from the year before.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
FHI Net Leverage
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
FHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.8 | Neutral |
| Stochastic | 60.5 | Neutral |
FHI's weekly RSI is 62 (neutral) and its Stochastic is 60 (neutral).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
FHI PE vs Financial Services Sector
| Metric | FHI | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 12% below |
| PE % | 55 | 63 | 8 pts below |
FHI is trading at 11x earnings, a 12% discount to the Financial Services sector's median of 13x.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
FHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $58.6 | 8.3% above |
| 20 week MA | $59.8 | 6.2% above |
| 50 week MA | $57.0 | 11% above |
| 100 week MA | $50.8 | 25% above |
| 200 week MA | $43.4 | 46% above |
FHI has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
FHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.7 | $28.5 | -13% |
| 2021 | $28.5 | $37.4 | +31% |
| 2022 | $37.4 | $35.7 | -4.4% |
| 2023 | $35.7 | $33.9 | -5.2% |
| 2024 | $33.9 | $41.4 | +22% |
| 2025 | $41.4 | $54.1 | +31% |
| 2026 YTD | $54.1 | $63.5 | +17% |
FHI has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.